Autopsy report · NCT04316169

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

“Funding and PI leaving institution”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Medical College of Wisconsin

Sponsor type

University, hospital or other

Conditions

Solid Tumor; Advanced Breast Cancer

Interventions

Abemaciclib; Hydroxychloroquine 200 mg; Faslodex; Anastrazole; Letrozole; Hydroxychloroquine 400 mg

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• SCD Fit Homebase Program
  “PI leaving institution” (85% match in meaning)
• PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer
  “Due to PI leaving the institution” (83% match in meaning)
• A Zero Acute Kidney Injury Strategy for Percutaneous Coronary Intervention in Patients With ChronicKidney Disease
  “The PI is leaving the institution” (81% match in meaning)
• Hemodynamic Effects Of Impella On Renal Circulation And Risk Of CA-AKI Among Patients Undergoing Protected PCI
  “PI may be leaving the institution” (79% match in meaning)
• Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
  “PI departure from institution” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.